Pfizer Stock News

The CDC found infants were 61% less likely to be hospitalized with Covid if their mothers received Pfizer or Moderna''s vaccine while pregnant.

Emily O’Reilly investigating commission’s failure to disclose texts to Pfizer chief on vaccines

Related Stocks: AMZN , CRM , TSLA , SPY , XLNX , CEF , PFE , CIVI , CIVI , MBB , DX , SAGAU , DWACU , PNM , BSN , DBDR , PONOU , ATSPT ,

The study found that infants under 6 months old were 61% less likely to be hospitalized with COVID-19 if their mothers had received a Pfizer or Moderna vaccination.

The Food and Drug Administration (FDA) pushed back a decision on whether to clear Pfizer’s COVID-19 vaccine for children under 5 because both arms of Pfizer’s clinical trial have a low number of COVID-19 cases, a Pfizer board member and former FDA commissioner says. “Since there’s a low number of cases overall in the clinical […]

The European Commission has approved Ngenla (somatragon), a long-acting recombinant human growth hormone to treat pediatric growth hormone deficiency, from Pfizer (PFE) and OPKO (OPK).

Pfizer <> announced that the European Medicines Agency ((EMA)) approved its 20-valent pneumococcal conjugate vaccine (PCV20). Read more on the product here.

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. NGENLA provides pediatric patients, their caregivers and healthcare providers wit

AstraZeneca and Pfizer are both table-pounding buys right now.

Washington, Feb 15 (PTI) A third dose of the Pfizer COVID-19 vaccine conferred higher effectiveness against infection and hospitalisation than two doses of the preventive after one month, a study has found. The study, published in The Lancet Regional Health-Americas, assessed the effectiveness of two doses of the Pfizer COVID-19 vaccination against infection, hospitalisation, and death […]

During the study period, 197,535 patients were infected with SARS-CoV-2, and of those 15,786 were admitted to the hospital.

What will result from the anticipated upcoming FDA meeting?

Is this discontinued drug from Pfizer nothing more than a drop in the bucket?

WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics license applications is expediting market growth. Primarily driven by favourable effective biopharmaceutical medications developed as a targeted therapy for cancer therapy, the total global Antibody Drug Conjugates (ADCS) Market is estimated to reach USD 13.17 Billion by 2028. The Market valued at a revenue of USD 4.24 Billion in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 18.9%. Furthermore, the rising benefit of Antibody Drug Conjugates (ADCS) as the unharmed healthy cells enable patients to recover quickly, thus growth of the Global Antibody Drug Conjugates (ADCS) Market, states Vantage Market Research, in a report, titled " Antibody Drug Conjugates (ADCS) Market by Application (Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer, Blood Cancer), by Technology (Cleavable Linker, Non-Cleavable Linker, Linkerless), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

This is the fourth positive phase-III study of rimegepant for the acute treatment of migraine, and the first to be conducted in the Asia Pacific The post Biohaven and Pfizer announce results of rimegepant trial for acute treatment of migraine appeared first on Express Pharma .